Abingworth raises $465 million for new life sciences fund

3 February 2021

Life sciences investment group Abingworth has announced the final closing of its latest transatlantic venture fund, Abingworth Bioventures 8 (ABV 8) at $465 million. ABV 8, which is Abingworth’s 13th life sciences fund, exceeded its target of $375 million and closed at its hard cap.

ABV 8 will target companies developing innovative therapeutics with potential to significantly improve human health. As with previous funds, ABV 8 will invest in opportunities in the USA, UK and Continental Europe.

ABV 8 will invest broadly across multiple stages including seed and early stage, development-stage companies, including VIPEs (Venture Investments in Public Equities), and Clinical Co-development opportunities. Total investment size per company will typically range from $15 million to $30 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK